Trials / Completed
CompletedNCT07478120
Muscle and Fat Mass in Preoperative Computed Tomography and a Neuromuscular Blocking Agent Dose
Relationship Between Muscle and Fat Mass Using Deep-learning Approach in Preoperative Computed Tomography and a Neuromuscular Blocking Agent Dose Required for Maintaining Deep Neuromuscular Blockade in Patients Undergoing Gynecological Surgery
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 31 (actual)
- Sponsor
- Seoul National University Bundang Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Deep neuromuscular blockade has benefits in various surgical procedures and reduces postoperative pain. While neuromuscular blockade dosages are often based on the patient's actual body weight, body composition can vary significantly depending on age, gender, and individual exercise levels. Therefore, uniformly estimating neuromuscular blockade dosages based on actual body weight can result in under- or over-administered neuromuscular blocking agents. Calculating neuromuscular blockade dosage based on actual body weight can be inaccurate, but it remains due to the difficulty of accurately quantifying human muscle and fat mass. Recent advances in image analysis techniques utilizing artificial intelligence models have led to the development of methods for quantifying muscle and fat mass from computed tomography (CT). Theoretically, a higher neuromuscular blockade dosage should be required as the muscle mass increases. This study aims to analyze the relationship between neuromuscular blocking agent dosage, onset time, profound blockade time, and recovery time, and muscle mass and fat mass calculated from preoperative CT scans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Neuromuscular block | Neuromuscular blockade monitoring |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2021-02-28
- Completion
- 2026-03-01
- First posted
- 2026-03-17
- Last updated
- 2026-03-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07478120. Inclusion in this directory is not an endorsement.